Realizing the promise of precision medicine in oncology
Details
We’re delighted to announce the launch of our TruSight™ Oncology Comprehensive (EU), our newest CE-marked IVD test for Comprehensive Genomic Profiling (CGP). Pathologists and Oncologists can now benefit from end-to-end solution that:
Detects majority of approved and emerging therapy biomarkers across multiple solid tumour types, including those in ESMO recommendations, EMA drug labels and local clinical trials
Maximizes ability to find actionable alterations, that can inform therapy regimens for cancer patients
Consolidates multiple individual iterative tests into a single CGP workflow, saving biopsy sample and precious time, so oncologists can make timely decisions for their patients
Has been validated by Illumina, is kitted and IVD labelled, so your organization can internalize the test and offer through your institutions
Visit Illumina booth 727 at AMP to discover how we’re helping laboratories advance precision genomics today while preparing for the future of genomic research.
Explore how local expertise, practical support and collaboration can help research teams move from ideas to insight. Join this live Illumina webinar to meet members of the Central Europe team and learn about the support available for research projects across the region. The session will introduce the local support ecosystem and discuss how Illumina teams can assist with workflow planning, applications, informatics and project conversations.